North west London is participating in the national rollout of Tirzepatide (Mounjaro®)—a new treatment being introduced in the NHS across England to support people living with obesity and serious related health conditions.
This is a phased national programme, meaning that groups of people will become eligible at different times during the rollout based on clinical criteria. Timings for the rollout are being finalised and will be shared as soon as possible. It is estimated that around 900 people in north west London will be eligible to receive Tirzepatide in the first group.
These individuals must meet national eligibility criteria:
- they must be aged 18 or over, have a BMI of 40 or higher (or 37.5 for some ethnic groups), and live with at least four of the NHSE defined obesity-related conditions, including type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, or sleep apnoea.
Tirzepatide will only be prescribed by the NHS as part of a comprehensive treatment plan developed by a multidisciplinary team. This means that anyone prescribed the drug must also engage with weight management support, including lifestyle changes, behavioural advice, and increased physical activity. The medication works best when combined with long-term support and commitment.
While Tirzepatide may not yet be available in all areas, we are working as quickly as possible to ensure there is equity of access across north west London. To support this, we are planning to expand Tier 3 Weight Management Services, so that more people can access high-quality support closer to where they live.
We are also developing plans to increase patient education and engagement, helping people understand how the medication works, what is expected of them, and how to make positive lifestyle changes alongside treatment. This will include personalised support and group-based sessions.
If you’re not in the first group to be eligible as part of the phased national roll out, there are still many ways to access weight management help. You can speak to your GP about a referral to a local Tier 3 weight management service, or ask about the NHS Digital Weight Management Programme, which is widely available across the NHS. These services can support your health now and may also help prepare for future access to new treatments.
NHS North West London and its partners are committed to supporting the safe, fair, and effective rollout of Tirzepatide as part of a wider effort to improve access to high-quality weight management care. Further updates will be added to this page over time.